- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05376124
Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory
Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory Hepatitis B: a Open Label, Prospective, Multi-center Cohort Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Yingren Zhao
- Phone Number: 18691232863
- Email: zhaoyingren@sohu.com
Study Contact Backup
- Name: Yushan Liu
- Phone Number: 15102901360
- Email: liuyushan233@163.com
Study Locations
-
-
-
Ankang, China
- Recruiting
- Ankang Central Hospital
-
Contact:
- Kui Li
- Phone Number: 13571422201
-
Hanzhong, China
- Recruiting
- Hanzhong 3201 Hospital
-
Contact:
- Yongmei Lin
- Phone Number: 13109188835
-
Jinan, China
- Recruiting
- Qianfhan Hospital
-
Weinan, China
- Recruiting
- weinan Central Hospital
-
Contact:
- Hongbin Li
- Phone Number: 13468902958
-
Wuhan, China
- Recruiting
- Wuhan Union Hospital
-
Xi'an, China
- Recruiting
- Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University
-
Contact:
- Nan Yang
- Phone Number: 13572227780
- Email: shmily.1989.2008@stu.xjtu.edu.cn
-
Xi'an, China
- Recruiting
- Second Affiliated Hospital of Xi'an JiaoTong University
-
Xi'an, China
- Recruiting
- Shaanxi Provincial People's Hospital
-
Xi'an, China
- Recruiting
- Tang-Du Hospital
-
Xi'an, China
- Recruiting
- Xi'an Central Hospital
-
Xi'an, China
- Recruiting
- Xijing Hospital of Air Force Medical University
-
Yan'an, China
- Recruiting
- Yan'an University Affiliated Hospital
-
Zhengzhou, China
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with refractory hepatitis B in January 2022 to January 2023 of The First Affiliated Hospital of Xi 'an Jiaotong University、The Second Affiliated Hospital of Xi 'an Jiaotong University、 Xijing Hospital Air Force Medical University 、Tang-du Hospital 、Shaanxi Provincial People's Hospital Xi 'an Central Hospital、 Ankang Central Hospital 、Yan 'an University Affiliated Hospital、 Hanzhong 3201 Hospital Weinan Central Hospital 、The First Affiliated Hospital of Shandong Medical University、Wuhan Union Hospital、The First Affiliated Hospital of Zhengzhou University.
All patients were required to sign written informed consent before enrollment
Description
Inclusion Criteria:
- (1) The diagnostic criteria of chronic hepatitis B: HBsAg and/or HBV DNA positive for more than 6 months; (2) Conforming to the definition of refractory hepatitis B (3) Aged between 18 and 70 (including 18 and 70); (4) Willing to accept treatment and sign informed consent.
Exclusion Criteria:
- (1) Pregnant women or lactating women; (2) with active HEPATITIS A, hepatitis C, and hepatitis D (in hospitals where conditions permit), hepatitis E and/or HIV infection; (3) Decompensated cirrhosis (Child-Pugh score 6); (4) Symptoms and signs of hepatocellular carcinoma, AFP> Patients with 100ng/ml of AFP would be excluded, but patients whose AFP remained stable (increased by less than 10%) for more than 3 months prior to the trial could be enrolled in patients whose liver tumors were excluded by liver imaging if AFP> 20ng/mL but 100ng/mL can be selected; (5) In addition to viral hepatitis, other history or evidence related to chronic liver disease (such as hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure, thalassemia); (6) a history of serious mental illness, especially depression severe mental illness is defined as at least 3 months before the above treatment dose antidepressant or antipsychotic drug treatment of severe depression or psychosis, or there are any medical history: once for attempted suicide was hospitalized due to mental illness, or had a disability due to mental illness; (7) a history of severe seizures or current use of anticonvulsants; (8) a history of chronic lung disease related to functional limitations; (9) A history of severe heart disease (NYHA grade III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmia requiring continued treatment, unstable angina or other important cardiovascular disease); (10) patients who are participating in other trials or have been treated with the study drug in the 12 weeks prior to screening; (11) Patients with a history of allergy to ETV, TDF and TAF; In addition to the above exclusion criteria, patients who meet any of the contraindications in the experimental drug description; (12) Unable or unwilling to provide informed consent or comply with the requirements of the study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
original therapy
ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
|
|
rescue therapy
TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
|
TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Negative HBV-DNA conversion
Time Frame: 48weeks
|
Negative HBV-DNA conversion at 48 weeks of treatment
|
48weeks
|
Liver hardness measurement
Time Frame: 3 years
|
3-year liver hardness measurement (LSM value)
|
3 years
|
Hepatocellular carcinoma
Time Frame: 3 years
|
Incidence and survival of hepatocellular carcinoma.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
virology indicators
Time Frame: 48weeks
|
virology indicators: quantitative hbv-dna;
|
48weeks
|
Biochemical indexes
Time Frame: 3 years
|
Biochemical indexes: ALT level;
|
3 years
|
Immunological indicators
Time Frame: 3 years
|
Immunological indicators: HBsAg level and HBsAg disappearance HBeAg serological conversion;
|
3 years
|
Drug-related adverse reactions
Time Frame: 3 years
|
Drug-related adverse reactions
|
3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Strain mutation indicators
Time Frame: 1year,2years and 3years
|
Strain mutation indicators: High-throughput sequencing was used to detect the presence of 5 preS1 deletion mutations at 1, 2, and 3 years after baseline treatment.
|
1year,2years and 3years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yingren Zhao, Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis B
- Hepatitis
- Hepatitis A
- Virus Diseases
- Hepatitis B, Chronic
Other Study ID Numbers
- XJTU1AF2021CRF-006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Virus Diseases
-
Institute of Tropical Medicine, BelgiumCompletedTransmission | Zika Virus | Zika Virus Disease | Virus SheddingBelgium
-
TakedaCompletedFlavivirus Infections | Healthy Participants | Virus, Zika | Zika Virus DiseaseUnited States, Puerto Rico
-
U.S. Army Medical Research and Development CommandActive, not recruiting
-
Emergent BioSolutionsCompletedZika Virus Infection | Zika Virus DiseaseCanada
-
U.S. Army Medical Research and Development CommandCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHealthy | Epstein Barr Virus InfectionUnited States
-
Valneva Austria GmbHEmergent BioSolutionsCompletedZika Virus Infection | Zika VirusUnited States
-
Merck Sharp & Dohme LLCCompletedVaricella Virus Infection
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsUnknown
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Zhongshan People's Hospital, Guangdong, ChinaRecruiting
Clinical Trials on original therapy
-
Assistance Publique - Hôpitaux de ParisTerminatedSchizophreniaFrance
-
Hannover Medical SchoolFresenius KabiCompletedSepsis | Systemic Inflammatory Response Syndrome | Critical Illness | AdultGermany
-
Jules Bordet InstituteRoche Pharma AGTerminated
-
Oslo University HospitalUniversity of Oslo; Norwegian National Advisory Unit on Rare Disorders (NKSD); Foreningen for MuskelsykeEnrolling by invitationHereditary Motor and Sensory Neuropathy | Polyneuropathies | Charcot-Marie-ToothNorway
-
Jiandong ZhangRecruiting
-
University of California, San DiegoNational Institute of Nursing Research (NINR)CompletedInactivityUnited States
-
Sarah BlaylockVA Office of Research and DevelopmentCompletedFall | Low VisionUnited States
-
Tufts Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingHeart Failure | Muscle AtrophyUnited States
-
University of British ColumbiaBritish Columbia Children's Hospital; Providence Health & ServicesCompletedPostoperative PainCanada
-
Bio-Strath AGZentrum für Adipositas- und Stoffwechselmedizin Winterthur GmbHUnknown